- Home
- SLP vs RCKT Comparison
SLP vs RCKT Comparison
Compare SLP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- RCKT
- Stock Information
- Founded
- SLP 1996
- RCKT 1999
- Country
- SLP United States
- RCKT United States
- Employees
- SLP N/A
- RCKT N/A
- Industry
- SLP EDP Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SLP Technology
- RCKT Health Care
- Exchange
- SLP Nasdaq
- RCKT Nasdaq
- Market Cap
- SLP 675.9M
- RCKT 764.5M
- IPO Year
- SLP 1997
- RCKT N/A
- Fundamental
- Price
- SLP $26.37
- RCKT $2.77
- Analyst Decision
- SLP Buy
- RCKT Buy
- Analyst Count
- SLP 8
- RCKT 11
- Target Price
- SLP $47.83
- RCKT $21.77
- AVG Volume (30 Days)
- SLP 296.7K
- RCKT 7.4M
- Earning Date
- SLP 07-01-2025
- RCKT 05-08-2025
- Dividend Yield
- SLP 0.23%
- RCKT N/A
- EPS Growth
- SLP N/A
- RCKT N/A
- EPS
- SLP 0.36
- RCKT N/A
- Revenue
- SLP $78,564,000.00
- RCKT N/A
- Revenue This Year
- SLP $30.21
- RCKT N/A
- Revenue Next Year
- SLP $11.83
- RCKT N/A
- P/E Ratio
- SLP $73.23
- RCKT N/A
- Revenue Growth
- SLP 21.49
- RCKT N/A
- 52 Week Low
- SLP $23.01
- RCKT $2.19
- 52 Week High
- SLP $50.11
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- SLP 31.23
- RCKT 27.94
- Support Level
- SLP $31.79
- RCKT $2.19
- Resistance Level
- SLP $34.01
- RCKT $2.67
- Average True Range (ATR)
- SLP 1.64
- RCKT 0.54
- MACD
- SLP -0.40
- RCKT -0.45
- Stochastic Oscillator
- SLP 0.78
- RCKT 11.72
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.